Your session is about to expire
← Back to Search
This trial is testing a gene therapy product, ADVM-022, for the treatment of neovascular or wet age-related macular degeneration (nAMD). The product is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with nAMD receiving anti-VEGF therapy in clinical practice.
- Age-Related Macular Degeneration (AMD)
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You are a male or female aged 50 years and above.You are willing and capable of providing written authorization for participation in this study.You have evidenced a significant reaction to anti-VEGF treatment.You possess present signs of active initial or recurrent sub-foveal CNV identified by Spectral Domain Optical Coherence Tomography (SD-OCT).Your visual acuity is between 20/32 and 20/320 according to the Early Treatment Diabetic Retinopathy Study (ETDRS) Snellen scale.Subjects must have been receiving anti-VEGF injections for wet AMD and had at least two treatments within the four months preceding screening.
- Group 1: Dose 1
- Group 2: Dose 2
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the main goals that researchers are hoping to achieve with this clinical trial?
"The primary objective of this study, as measured over a 50-week period, is to evaluate the mean change in best corrected visual acuity (BCVA) from baseline. In addition to the primary outcome, this trial will also be assessing secondary outcomes including mean change in BCVA from baseline (as measured by ETDRS), percentage of participants who are supplemental aflibercept injection-free (defined as no supplemental anti-VEGF treatments required post therapy), and percentage of participants without CST fluctuations > 50 μm (defined as no significant changes in central subfield thickness)."
Can new volunteers still sign up for this experiment?
"Yes, according to the clinicaltrials.gov website, this study is looking for patients right now. The listing says that the trial was first posted on 8/23/2022 and edited on 9/8/2022. They are recruiting for 72 participants from 5 different locations."
When might we see ADVM-022 on the market?
"ADVM-022 falls into the Phase 2 category, which means that while there is evidence of safety, none exists yet for efficacy. Consequently, we have given it a score of 2."
What is the total sample size for this research project?
"That is correct, the information available on clinicaltrials.gov seems to suggest that this trial is actively looking for patients right now. This particular trial was posted on 8/23/2022 and then edited last on 9/8/2022. They are hoping to enroll 72 patients at 5 different sites."
How many hospitals are running this trial?
"Right now, this research is ongoing at 5 different sites. They are situated in cities like Phoenix and Fullerton as well as Aiea. If you want to reduce the amount of travelling needed, be sure to select a location near you."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What site did they apply to?
Why did patients apply to this trial?
Share this study with friends